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Acquired Cisplatin Resistance in Human Ovarian Cancer Cells Is Associated with
Enhanced Repair of Cisplatin-DNA Lesions and Reduced Drug Accumulation
Ricardo J. Parker,* Alan Eastman,t Frieda Bostick-Bruton,* and Eddie Reed*
*Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892; and *Department ofPharmacology
and Toxicology, Dartmouth Medical School, Hanover, New Hampshire 03755
Abstract
Studies were undertaken to investigate acquired resistance to
cisplatin in human ovarian cancer cells. The cell lines A2780
and A2780/CP70 were studied to assess their respective char-
acteristics of drug accumulation and efflux, cytosolic inactiva-
tion of drug, and DNA repair. All experiments were performed
using 1-h drug exposures. The A2780/CP70 cell line was 13-
fold more resistant to cisplatin than A2780 cells. When studied
at their respective IC50 doses, drug accumulation rates were
similar for the two cell lines. However, the resistant cell line
was twofold more efficient at effluxing drug, which was asso-
ciated with reduced total drug accumulation for equivalent mi-
cromolar drug exposures. At equivalent levels of total cellular
drug accumulation, the two cell lines formed the same levels of
cisplatin-DNA damage, suggesting that cytosolic inactivation
of drug does not contribute to the differential in resistance be-
tween these cell lines. Resistant cells were also twofold more
efficient at repairing cisplatin-DNA lesions in cellular DNA
and in transfected plasmid DNA. We conclude that in these
paired cell lines, alterations in drug uptake/efflux and in DNA
repair are the major contributing factors to acquired resistance
to cisplatin. (J. Clin. Invest. 1991. 87:772-777.) Key words:
cisplatin * ovarian cancer * resistance * DNA repair * atomic
absorption spectrometry * chloramphenicol acetyltransferase.
pRSVcat
Introduction
The cytotoxicity of cis-diamminedichloroplatinum(II) (cispla-
tin) against cells in culture has been found to be directly related
to total platinum binding to DNA (1), to cisplatin-DNA inter-
strand cross-links (2), and to the formation of intrastrand bi-
dentate diammineplatinum-DNA adducts at the N7 positions
ofthe d(GpG) and d(ApG) sites in DNA (3, 4). Consistent with
the above observations, recent studies suggest that DNA repair
capacity for one or more of these lesions may be a major deter-
minant of resistance to cisplatin in L1210 cells (5), human
ovarian cancer cells (6), human testicular cancer cells, and hu-
man bladder cancer cells (7).
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Studies of the relationship ofDNA repair to cisplatin resis-
tance in mammalian cells are being conducted by several
groups. The most extensive studies done to date are those of
Eastman and colleagues in L12 10 cells in which varying levels
of acquired resistance to cisplatin has been developed (5, 8). In
those studies, HPLC techniques were used to show that resis-
tant sublines were much more effective at removing cisplatin-
DNA lesions from cellular DNA as compared with the more
sensitive sublines. However, the extent of repair did not corre-
late completely with the extent of resistance to cisplatin, sug-
gesting that enhanced DNA repair was one of several determi-
nants of the level of resistance in L 12 10 cells. Using immuno-
chemical methodology, Bedford and colleagues reported that
cisplatin-resistant human bladder cancer cell lines have greater
capacity to remove intrastrand adducts from cellular DNA
than relatively sensitive testicular cancer cell lines (7). It is un-
clear whether these antibody techniques measure DNA lesions
that are unique to the antibody, or are consistent with other
techniques such as HPLC or atomic absorption spectrometry
(AAS)' (9). Immunochemical methodology has been used by
Reed and colleagues to investigate drug binding to DNA and its
relationship to cell kill after therapeutic levels ofdrug exposure
in human ovarian cancer cells in vitro (10). When sensitive and
resistant sublines ofA2780 were studied, cells which were more
resistant to cisplatin required more drug binding to DNA to
effect the same level of cell kill. Maduda and colleagues have
shown that total cisplatin-DNA damage is related to cytotoxic-
ity in human ovarian cancer cells and that aphidicholin can
inhibit the repair of that damage and thereby increase cell kill
(1 1). Using another assay for DNA repair, Lai et al. have also
reported that in human ovarian cancer cells, increased levels of
unscheduled DNA synthesis is associated with resistance to
cisplatin (6).
Although these studies suggest that DNA repair may be
important in platinum drug resistance in human ovarian
cancer, no studies have been published to date which directly
address the relative contributions of drug uptake and repair of
DNA damage in human ovarian cancer cells. We therefore
investigated drug uptake and DNA repair of cisplatin-DNA
lesions in the human ovarian cancer cells A2780 and
A2780/CP70. These experiments involved measurements of
sensitivity to cisplatin, AAS measurements of total drug accu-
mulation and efflux by these cells, AAS measurements of ad-
duct formation and removal from cellular DNA, and the rela-
1. Abbreviations used in this paper: AAS, atomic absorption spectrome-
try; CAT, chloramphenicol acetyltransferase; d(ApG), adjacent ade-
nine and guanine moieties in an intact DNA strand; d(GpG), adjacent
guanine moieties in an intact DNA strand; IC50, dose of drug that
reduces survival rate in a cell line to 50% of the control value; IC90,
dose ofdrug that reduces survival rate in a cell line to 10% ofthe control
value (90% cell kill); pRSVcat, designation given to the plasmid used in
these studies by its developers (see reference 16).
772 R. J. Parker, A. Eastman, F. Bostick-Bruton, and E. Reed
J. Clin. Invest.
© The American Society for Clinical Investigation, Inc.
0021-9738/91/03/0772/06 $2.00
Volume 87, March 1991, 772-777
tive abilities of these cell lines to reactivate cisplatin-damaged
plasmid DNA.
Methods
Cell culture. The ovarian cancer cell lines A2780 and A2780/CP70
were generously provided by Dr. Robert Ozols. The L12 10/0 cell line
has been previously characterized (5, 8). Ovarian cancer cells were cul-
tured in monolayer using RPMI 1640 media, supplemented with 10%
FCS, 0.2 U/ml of human insulin, and penicillin/streptomycin (Gibco,
Grand Island, NY). Cells were grown in a humidified 5% CO2 mixture
with ambient air at 37°C. L 1210 cells were grown in suspension under
similar conditions, but with the absence of insulin in the medium.
Sensitivity to cisplatin in ovarian cancer cells was assessed in colony
growth assays using six well plates, each well 35 mm in diameter. Cells
were plated at 500 cells per well and cisplatin treatments were per-
formed as 1-h drug exposures on the day after plating. Cisplatin was
initially dissolved in sterile phosphate buffered saline at I mg/ml, and
dilutions from this 1 mg/ml solution were made into RPMI media to
obtain the desired drug treatment concentration. Cells were allowed to
grow for a period of 7- 10 d, at which time colonies were stained with a
methylene blue solution of 0.167 g% in absolute methanol. Visible
colonies were counted by hand. Drug treatments were done in tripli-
cate at each dose in each individual experiment. The value obtained in
wells where no drug was added was assigned the value of 100% growth.
Measurement ofcellular drug accumulation rate and efflux. A2780
and A2780/CP70 cell lines were treated at their respective IC50 cispla-
tin doses for the purpose of measuring cellular drug accumulation and
efflux. Cells were exposed to cisplatin for I h in all experiments. To
measure drug accumulation, we harvested cells at 30 min and 1 h. To
measure drug efflux, cells were treated for I h and harvested at the
following time points: 30 min after drug removal, 1 h, 2 h, and 4 h.
Total cellular drug accumulation and efflux in these two cell lines were
compared by assigning the value of 100% to that drug level achieved at
1 h, and assessing all other values relative to the 100% value.
Measurement ofplatinum in cellular DNA and cellular drug accu-
mulation. In one set ofexperiments, we sought to establish the relation-
ship between cisplatin dose and cisplatin-DNA adduct formation in the
sensitive and resistant cell lines. Both cell lines were treated in mono-
layer with cisplatin doses of 0, 10, 20, 40, or 60 AM cisplatin for 1 h;
cells were immediately harvested; DNA was isolated (12) and mea-
sured by absorbance at 260 nm; and total platinum per unit DNA was
measured by AAS (13). In a separate set of experiments both cell lines
were treated under the same conditions for the purpose of measuring
cellular accumulation ofdrug. After a 1-h exposure, cells were immedi-
ately harvested and frozen at -20°C. The cell pellets were later "wet-
ashed" according to the method of McGahan (14), and total cellular
drug accumulation was measured as femtomoles of platinum per 107
cells.
To assess the ability of these cells to remove platinum from cellular
DNA, cells were plated in T- 150 flasks and allowed to grow in log phase
with changes of fresh media twice weekly. Cells were labeled with 3H-
thymidine, using media with a 3H-thymidine concentration of0.1 MCi/
ml. Cells were labeled with 3H overnight, after which fresh media was
placed onto the cells and incubation was again carried out overnight.
At this time, cells were exposed to various cisplatin drug concentrations
for 1 h. In designated experiments, cells were treated at their respective
IC50s, as was assessed by colony formation (see above). In other experi-
ments, the A2780 cell line was incubated with 22 MM drug to obtain a
level of DNA platination equivalent to that obtained in the
A2780/CP70 cell line after its IC50 exposure of 40 MM. The 22-juM
drug dose was based on extrapolation from the linear regression equa-
tion for A2780 cells from Fig. 3 (see below). After 3H labeling, an
aliquot ofcells was harvested before drug treatment (time zero). After a
1-h drug exposure, cells were harvested at the following time points: 1 h
(immediately at the end of the cisplatin exposure), 3, 5, 7, and 24 h.
Cells were frozen immediately at -20°C.
DNA was isolated on cesium chloride density gradients, yielding
DNA which was 99.6% free of contamination (12). This DNA was
dialyzed against four exchanges of double distilled water over - 36 h.
DNA was then measured by absorbance at 260 nm. 3H-Thymidine
content was assessed by liquid scintillation counting and platinum con-
tent was assessed by AAS (13). A decrease in the specific radioactivity
ofDNA (disintegrations per minute per microgram DNA) at each time
point compared to that obtained at 1 h represents the amount ofreplica-
tion that occurred. This ratio was used to correct the values ofplatinum
content of cellular DNA.
Reactivation studies of cisplatin-damaged pRSVcat. The JM-109
strain of E. coli, containing the plasmid pRSVcat, was generously pro-
vided by the laboratory of Dr. Bruce Howard of the National Cancer
Institute. Plasmid was grown and purified using standard growth pro-
cedures and the alkali lysis method as described by Maniatis (15). Puri-
fied pRSVcat was platinated according to the method of Eastman in
0.02 M sodium perchlorate, pH 5.5 (16). The level of plasmid platina-
tion was confirmed by AAS. Plasmid was transfected into ovarian
cancer cells using a modification of the DEAE-dextran method (17).
Immediately after trypsinization, transfection was carried out with cells
in suspension, using 3-5 x 106 cells in I ml ofmedia with a DEAE-dex-
tran concentration of 250 Mg/ml and a defined quantity of plasmid for
3 h. After completion of the transfection exposure, cells were pelleted,
washed, resuspended in fresh media, and plated in monolayer. Cells
were harvested at 48 h and CAT activity was measured according to the
method of Neumann (18) as modified by Eastman (19). The level of
chloramphenicol acetyltransferase (CAT) activity associated with zero
level of cisplatin molecules per plasmid was assigned a value of 100%
CAT activity and the CAT activity associated with damaged plasmid
was assessed relative to this control value.
Measurement of efficiency ofpRSVcat transfection. The effect of
different levels of platinum modification on the transfection efficiency
of the pRSVcat plasmid was assessed using a modification ofthe trans-
fection method described above. Plasmid was prepared in a standard
fashion with the exception of the addition of 3H-thymidine to the E.
coli culture medium at a concentration of 0.1 MCi/ml. 3H-labeled
pRSVcat was harvested as described above and the specific activity of
the 3H relative to plasmid DNA was assessed. 3H-labeled pRSVcat was
then platinated as outlined above. Cisplatin-modified, 3H-labeled,
pRSVcat plasmid was then transfected into the respective cell lines. 50
,ug of plasmid DNA and 3-6 x 106 cells were used for each transfection.
After the 3-h transfection period cells were washed, exposed to 1 Mg/ml
of DNase for 15 min at 37°C to remove extracellular DNA, and then
washed again. The amount of 3H activity transfected into cells with
plasmid that contained no platinum was assigned 100% transfection
activity, and plasmid with increasing levels of platination was assessed
relative to this control value.
Results
Differences in survival between cell lines. The relative sensitiv-
ity of the two cell lines to cisplatin as assessed by colony forma-
tion is shown in Fig. 1. The IC50 of cisplatin, based on a 1-h
drug exposure, is 3 MM in the A2780 cell line; the IC90 is
reached at 30MgM. By contrast, in the A2780/CP70 cell line, the
IC50 is reached at 40 ,uM and the IC90 is reached at 100 ,M.
The difference between the cell lines in the IC50 drug dose
demonstrates a 13-fold difference in cellular sensitivity to cis-
platin for these two cell lines.
Measurement ofcellular drug accumulation and efflux. We
measured the relative rates of cellular accumulation and efflux
of cisplatin, during and after 1-h exposures to IC50 drug doses
in the two cell lines. Shown in Fig. 2 are data for A2780 (IC50
= 3 MM) and A2780/CP70 (IC50 = 40 ,M) with each data
point representing the mean of four determinations. When as-
sessed as a percentage of maximal drug accumulation, the two
Cisplatin Resistance and DNA Repair 773
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Figure 1. Sensitivity to cisplatin was assessed by colony formation
assay in A2780, wild type cells (solid diamonds) and A2780/CP70
cells (open squares). Cells were plated at 500 cells per well; drug
exposures were for 1 h in triplicate wells; cells were grown for 7-10
d; visible colonies were counted by hand; and values were expressed
relative to those wells where no drug was used (100% control value).
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cell lines accumulated drug at the same rate over the 1-h time
period. At 30 min of the 1 h exposure, A2780 accumulated
58.5% of total cellular platinum and A2780/CP70 accumu-
lated 52.5% (Fig. 2 A).
We then measured drug efflux over 4 h, after a 1-h treat-
ment with IC50 drug doses (Fig. 2 B). For A2780, cellular plati-
num levels changed gradually during the observation period,
and at the end of 4 h a total of 27.4% of accumulated cellular
platinum had been removed from these cells. Cisplatin-resis-
tant A2780/CP70 cells demonstrated enhanced efflux as com-
pared to A2780 cells. After 4 h, 51.4% of accumulated cellular
platinum had been removed.
Measurement ofdrug-DNA binding after defineddrug expo-
sures. We sought to establish the level ofcisplatin-DNA adduct
formation in the two cell lines after equivalent cisplatin drug
exposures (Fig. 3). Each data point is the mean and standard
deviation of four determinations. In the sensitive cell line, the
relation between drug dose and adduct level approaches linear-
ity up to 40 uM, and then appears to plateau. Linear regression
analysis of these data up to the cisplatin dose of 40 MM yields
the equation y = 1.2x + 2.6, r = 0.98, and through the dose of
60 ,M, the linear regression equation is y = 0.96x + 0.74, r
= 0.94. In the resistant cell line the relation also approaches
linearity, and the equation of the linear regression analysis is y
= 0.55x + 0.77, r = 0.97. Based on the slopes of the linear
portions of the curves, approximately twofold more cisplatin
was needed in the resistant cells to attain the same level ofDNA
damage. These values also demonstrate that 1 Pt/ 106 nucleo-
tides produces an IC50 in A2780 cells while 1 Pt/1.4 X 105
nucleotides produces a comparable toxicity in A2780/CP70
cells. The former value is consistent with the published value
for L1210 cells at their IC50 (5, 8).
Assessment oftotal cellular accumulation ofdrug. We next
measured cellular accumulation of cisplatin under the condi-
tions used to measure drug-DNA binding as discussed above.
Fig. 4 shows these data with each data point representing the
mean and standard deviation of four determinations. As was
the case with respect to DNA binding, the relationship between
drug dose and total cellular accumulation of drug approached
linearity for both cell lines. In the sensitive cell line, the linear
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Figure 2. Cellular drug accumulation (A) and efflux (B) were
determined in A2780 (open squares) and A2780/CP70 (solid
diamonds) during and after IC50 drug exposures for I h. The IC5Os
were: A2780, 3 ALM; A2780/CP70, 40 MM. Cells were treated as
described in the text. Each data point is the mean of four separate
determinations. Absolute values for drug uptake in the respective cell













Figure 3. Total DNA bound platinum was measured in A2780, wild
type cells (open squares) and A2780/CP70 cells (solid diamonds)
after defined drug exposures for I h. Cells were harvested immediately
after drug exposure. DNA was isolated by cesium chloride bouyant
density gradient centrifugation, and total platinum content was
measured using atomic absorption spectroscopy with Zeeman
background correction. Each data point is the mean and standard
deviation from four separate determinations.
























Figure 4. Total cellular accumulation of drug was measured in
A2780, wild type cells (open squares) and A2780/CP70 cells (solid
diamonds) after defined drug exposures for 1 h. Cells were washed
with PBS, trypsinized, and "wet-ashed" as described in the text. Each
data point is the mean and standard deviation from four separate
determinations.
resistant cell line the equation is y = 0. Ox + 0.50, r = 0.97.
Based on the slopes of the linear portions of the curves, about
twofold more drug is needed in the resistant cells to attain the
same level of cellular drug accumulation. When data on cellu-
lar accumulation are directly compared with DNA adduct
level, the two cell lines form curves that are virtually superim-
posable (Fig. 5). Thus, the level of drug uptake is the primary
determinant of DNA adduct level in these two cell lines and
cytosolic drug inactivation appears not to be a factor in deter-
mining any difference between cell lines in the amount of
DNA-bound drug. For example, both cellular accumulation of
drug and DNA platination are equivalent in the two cell lines at
the respective cisplatin doses of 20 ,M in the A2780 cells, and
40 MM in A2780/CP70 cells.
Removal ofplatinumfrom cellular DNA. For the purpose of
comparing the two cell lines in their respective ability to re-
move platinum from cellular DNA, two approaches were
taken. In the first, an IC50, 1-h dose was chosen for treating the
respective cell lines, and we followed platinum removal from
cellular DNA with time. In the second approach, we compared
the sensitive cell line with the resistant cell line when both were
"loaded" with the same level ofDNA bound cisplatin (Fig. 6).
After an IC50 dose in the A2780 cell line, the peak plati-
num level seen after exposure was 1.0 pg/Ag DNA (Fig. 6). This
was followed by a 6-h phase of rapid removal from cellular
DNA to a level of 0.5 pg/ag DNA. This was followed by a
plateau, indicating no further removal of platinum during the
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Figure 5. Data shown in Figs. 3 and 4 are transposed to give plots of
drug accumulation versus DNA adduct level in the two ovarian
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Figure 6. The removal of elemental platinum from cellular DNA with
time was assessed in the two cell lines in three different sets of
experiments. In one set, A2780, wild type cells were treated at their
IC50 dose of 3 ,M for I h and total platinum per unit DNA was
measured at defined time points after the beginning of the cisplatin
exposure (solid diamonds). In a second set of experiments, A2780/
CP70 cells were treated at their IC50 dose of40 MM for 1 h and total
platinum per unit DNA was followed (open squares). In a third set,
A2780, wild type cells were treated with 22 MM cisplatin for 1 h so
as to attain a level ofDNA modification equivalent to that seen in the
resistant cell line after its 40 MM exposure (closed squares). Each data
point is the mean and standard deviation from three or from four
separate determinations.
A2780/CP70 cell line, after an IC50 dose which is 13-fold
higher than the A2780 IC50 dose, the peak platinum level was
4.3 pg/,ug DNA (Fig. 6). A phase of rapid removal occurred
over the next 4 h, down to a level of 1.6 pg platinum per ug
DNA. This was followed by a plateau phase during the re-
mainder of the 24-h period ofobservation. Therefore, in terms
of the absolute quantity of platinum, the peak levels seen after
an IC50 exposure is fourfold higher in the resistant cell line
than in the sensitive cell line.
When viewed as a percentage ofthe maximal value of plati-
num bound to DNA, the resistant cell line removed 63% of its
total platinum load from cellular DNA in the first 6 h, whereas
the sensitive cell line was capable of removing only 50%. In
both cases, this was after IC50 drug exposures. When assessed
as absolute quantity of adduct, the amount of platinum re-
moved from cellular DNA during the observation period is
fivefold greater in the resistant cell line. In both cell lines, some
portion of the adduct load persists for at least 24 h after the
cisplatin exposure. The amount ofadduct that persists is three-
fold greater in the resistant cell line as compared to the sensitive
cell line (1.6 vs. 0.5 pg/,ug DNA).
Also in Fig. 6 are data from the sensitive cell line when
incubated at a cisplatin dose of22 MM. At this dose, the adduct
level at 1 h was 4.8 pg/4g DNA, which approximates the adduct
level seen in the resistant cell line when treated at its IC50 of40
MM. Over the next 6 h, the adduct level was reduced to 3.1
pg/,ug DNA: i.e., 35% of the total platinum load was removed.
This was followed by a plateau, as was seen in the other two
cases. As shown, the sensitive cell line is less able to remove
cispla'tin from its cellular DNA when loaded to this level of
platination (35% removal over 6 h, vs. 63% removal in the
resistant cell line).
Efficiency of transfection ofpRSVcat. Studies were per-
formed in the two cell lines to assess the influence of plasmid
platination on the relative efficiency of transfection of
pRSVcat. Levels of plasmid platination studied included 0, 5,
10, 20, and 40 platinum molecules per plasmid. In these exper-













iments, we assessed the relative efficiency of transfection as
that percentage of plasmid that was associated with the cell
after DNase treatment. In both the A2780 and the
A2780/CP70 cell lines, the total percentage of control plasmid
that was associated with the cells after DNase treatment was
< 3% (data not shown). In each experiment, the level of plas-
mid platination did not substantively alter the amount of plas-
mid that was transfected into cells (Fig. 7).
Different activities ofhost cell reactivation ofpRSVcat. To
compare the cell lines' abilities to reactivate the pRSVcat plas-
mid, transfections were performed in three cell lines using a
single batch of pRSVcat. The A2780 and A2780/CP70 cell
lines were studied, along with the L 1210/0 cell line which
served as an internal control in these experiments because it is
known to perform virtually no repair of cisplatin-DNA lesions
(8, 16). Data from these cell lines are shown in Fig. 8. In the
L 1210/0 cell line, host cell reactivation ofpRSVcat was totally
consistent with what has been previously reported, with a Bo
(amount of DNA damage constituting one lethal hit to trans-
fected plasmid DNA) of five platinum molecules per plasmid
(8, 16). Levels of CAT activity equivalent to 100% of control
were seen in the A2780 cell line up to a modification level of
eight platinum molecules per plasmid. In the A2780/CP70 cell
line, 100% ofcontrol activity was seen at modification levels up
to 16 platinum molecules per plasmid. Levels ofCAT activity
< 10% of control were seen at 32 platinum molecules per plas-
mid in the sensitive cell line, and 56 molecules per plasmid in
the resistant cell line. When these data are represented graphi-
cally, the Bo-for the two cell lines (37% control activity) differ by
a factor ofapproximately two: 16 platinum molecules per plas-
mid in the sensitive cell line, and 27 molecules per plasmid in
the resistant cell line.
Discussion
The A2780/CP70 cell line exhibits acquired resistance to cis-
platin which resulted from continuous stepwise exposure to
cisplatin over many months (6), and was derived from the rela-
tively cisplatin-sensitive A2780 cell line. The resistant cell line
shows a twofold reduced drug accumulation, enhanced drug
effilux, and twofold reduced DNA platination. For a given level
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Figure 7. The effect of cisplatin modification on the transfection
efficiency of pRSVcat into A2780, wild type cells (solid bars) or
A2780/CP70 cells (hatched bars) was assessed by preparing 3H-labeled
plasmid, modifying that plasmid with cisplatin, and then transfection
into the respective cell line. After transfection, cells were DNase
treated and immediately placed into scintillation fluid for assessment
of cellular 3H content. Each bar represents the mean and standard
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Figure 8. Host cell reactivation of cisplatin-damaged pRSVcat was
assessed as the percent reduction from control levels ofCAT activity,
as a function of the level of cisplatin modification. Transfection was
carried out with cells in suspension, using 3-5 x 106 cells in 1 ml of
media with a DEAE-dextran concentration of 250 ig/ml. 10 Ag of
plasmid was used for each transfection. Each data point is the mean
of two to three determinations.
regardless of the cell line. Increased levels of cytosolic sulfhy-
dryl-containing proteins has been described as inducing cis-
platin resistance in human ovarian cancer cells. Whereas pub-
lished evidence supports the contention that drug inactivation
in the cytosol by metallothionein (20) and/or glutathione (21)
may contribute to cisplatin resistance, our data suggests that in
these cells, this mechanism does not contribute to the differen-
tial in resistance. The drug-resistant cells also show an in-
creased ability to remove platinum from cellular DNA as com-
pared to the sensitive cell line, and show an augmented ability
to reactivate the pRSVcat plasmid after cisplatin-induced
DNA damage. These independent measures of DNA repair
capability are both enhanced in the cisplatin-resistant cell line
by a factor of two.
To assess platinum removal from cellular DNA, these cell
lines were compared at their respective IC50 doses so as to
obtain measures ofhow these cells handle biologically relevant
levels ofdrug-induced DNA damage. The IC50 doses were cho-
sen because they represent at least one measure of biologically
equivalent drug doses. After the 1-h cisplatin exposure, at least
fourfold more cisplatin-DNA damage is necessary in the resis-
tant cell line to attain the same level of cell kill as in the sensi-
tive line. We obtained these measurements using atomic ab-
sorption spectrometry which measures total DNA bound drug
after cisplatin exposures (13). Atomic absorption spectrometry
is possibly a more reliable assessment oftotal DNA bound drug
than other methods of adduct measurement thus far reported
(22). However, there is debate as to whether total DNA bound
drug is of primary importance, or ifone or more of the defined
specific platinum-DNA lesions is of primary importance in
inducing cell kill (22).
The ability to "reactivate" UV-damaged or chemically dam-
aged plasmid or viral genomes that have been introduced into
cells is related to DNA repair capability. This has been shown
for various cell lines using a number of strains of adenovirus
(23-25) and using UV-damaged or cisplatin-damaged
pRSVcat (8, 16, 26). In this study, the relative abilities of these
cell lines to reactivate cisplatin-damaged pRSVcat parallels the
cell lines' abilities to remove platinum from cellular DNA,
when these cells are DNA-modified to the same level with cis-
platin. This suggests that host cell reactivation in this setting
may serve as an indication of a cell line's relative ability to
perform repair of cisplatin-DNA lesions.
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Direct and indirect evidence suggests that DNA repair may
also be important in human ovarian cancer in vivo. Cisplatin-
DNA adduct persistence is directly contributory to measured
adduct level in human leukocytes (27), which in turn is directly
related to disease response (27-29). Data presented in this re-
port demonstrate that adduct persistence at 24 h after cisplatin
exposure is inversely related to DNA repair capability. In UV
repair-deficient Chinese hamster ovary cells of complementa-
tion group I, transfection of the human DNA repair gene
ERCC 1 confers fivefold resistance to cisplatin and confers the
ability to remove cisplatin from cellular DNA (30). Prelimi-
nary data show that expression of ERCC 1 in fresh ovarian
cancer tumor tissue is directly related to a patient's response to
single-agent carboplatin chemotherapy (Dabholkar, M., and E.
Reed, unpublished observations). The current report shows
that a specific increase in the ability to repair cisplatin-DNA
lesions is a major component, but not the only component, of
acquired cisplatin resistance in human ovarian cancer cells.
In all human cell lines thus far studied, it is now apparent
that cisplatin drug resistance is a multifactorial process which
may exist as a combined function ofdrug uptake, DNA repair,
and/or cytosolic drug inactivation. In established human ovar-
ian cancer cell lines which differ biologically in that one has
acquired in vitro resistance to cisplatin, the resistant cell line
has reduced drug accumulation that correlates with reduced
DNA platination. This suggests that cytosolic drug inactivation
is not a contributor to the differential in resistance in these
cells, and reduced DNA platination only accounts for twofold
resistance. The other identified contributor to resistance is the
enhanced DNA repair capability for cisplatin-DNA damage, as
assessed by removal of total platinum from cellular DNA and
the enhanced ability to repair cisplatin-damaged pRSVcat.
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